KYMR: STAT6 program advances with phase IIb data expected by year-end, supporting phase III plans
The conference highlighted advances in targeted protein degradation, with lead programs STAT6 and IRF5 progressing through clinical stages. STAT6 showed strong efficacy and safety in atopic dermatitis, with phase IIb data expected by year-end and phase III studies planned.Based on Kymera Therapeuti…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.